Apollomics (APLM) Competitors $9.52 -0.04 (-0.42%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends APLM vs. KZR, ALRN, CELU, NBRV, VIRI, ITRM, SCYX, VYNE, DTIL, and VTVTShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Kezar Life Sciences (KZR), Aileron Therapeutics (ALRN), Celularity (CELU), Nabriva Therapeutics (NBRV), Virios Therapeutics (VIRI), Iterum Therapeutics (ITRM), SCYNEXIS (SCYX), VYNE Therapeutics (VYNE), Precision BioSciences (DTIL), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Kezar Life Sciences Aileron Therapeutics Celularity Nabriva Therapeutics Virios Therapeutics Iterum Therapeutics SCYNEXIS VYNE Therapeutics Precision BioSciences vTv Therapeutics Kezar Life Sciences (NASDAQ:KZR) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership. Does the MarketBeat Community prefer KZR or APLM? Kezar Life Sciences received 132 more outperform votes than Apollomics when rated by MarketBeat users. However, 80.00% of users gave Apollomics an outperform vote while only 56.90% of users gave Kezar Life Sciences an outperform vote. CompanyUnderperformOutperformKezar Life SciencesOutperform Votes13656.90% Underperform Votes10343.10% ApollomicsOutperform Votes480.00% Underperform Votes120.00% Do insiders & institutionals have more ownership in KZR or APLM? 67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 9.3% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is KZR or APLM more profitable? Apollomics' return on equity of 0.00% beat Kezar Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kezar Life SciencesN/A -54.95% -46.11% Apollomics N/A N/A N/A Which has stronger valuation & earnings, KZR or APLM? Kezar Life Sciences has higher revenue and earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKezar Life Sciences$7M6.60-$101.87M-$13.18-0.48Apollomics$1.22M8.51-$172.60MN/AN/A Do analysts rate KZR or APLM? Kezar Life Sciences currently has a consensus price target of $39.50, indicating a potential upside of 524.01%. Apollomics has a consensus price target of $200.00, indicating a potential upside of 2,000.84%. Given Apollomics' stronger consensus rating and higher possible upside, analysts clearly believe Apollomics is more favorable than Kezar Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kezar Life Sciences 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Apollomics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, KZR or APLM? Kezar Life Sciences has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Does the media favor KZR or APLM? In the previous week, Kezar Life Sciences had 1 more articles in the media than Apollomics. MarketBeat recorded 1 mentions for Kezar Life Sciences and 0 mentions for Apollomics. Kezar Life Sciences' average media sentiment score of 0.98 beat Apollomics' score of 0.00 indicating that Kezar Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Kezar Life Sciences Positive Apollomics Neutral SummaryApollomics beats Kezar Life Sciences on 8 of the 15 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.38M$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A10.0188.8317.53Price / Sales8.51335.351,284.8380.47Price / CashN/A22.6336.6032.90Price / Book0.205.084.964.69Net Income-$172.60M$154.90M$117.89M$224.57M7 Day Performance-5.93%2.59%2.74%3.33%1 Month Performance-2.36%1.52%3.63%5.33%1 Year Performance-89.34%5.49%27.26%22.97% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics2.3923 of 5 stars$9.52-0.4%$200.00+2,000.8%-89.3%$10.38M$1.22M0.0045KZRKezar Life Sciences3.9267 of 5 stars$6.30-3.2%$39.50+527.0%-25.4%$45.97M$7M-0.4860ALRNAileron Therapeutics2.8718 of 5 stars$2.11+9.3%$19.00+800.5%N/A$45.72MN/A-0.689CELUCelularity0.3696 of 5 stars$2.07-4.2%N/A-21.8%$45.51M$48.20M0.00220Short Interest ↑Gap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M-0.0770VIRIVirios TherapeuticsN/A$2.36-0.8%$3.00+27.1%+130.6%$45.45MN/A-8.745Gap UpITRMIterum Therapeutics1.8957 of 5 stars$1.64-0.6%$5.00+204.9%-18.9%$45.13MN/A-0.8210Positive NewsSCYXSCYNEXIS0.3456 of 5 stars$1.18-4.1%N/A-38.8%$44.78M$8.57M-1.5960Positive NewsVYNEVYNE Therapeutics3.8391 of 5 stars$3.02-12.0%$6.88+127.6%+51.7%$44.55M$493,000.00-3.5130DTILPrecision BioSciences4.4668 of 5 stars$5.74+0.7%$37.67+556.2%-56.6%$44.03M$75.10M95.68200Short Interest ↑VTVTvTv Therapeutics1.635 of 5 stars$13.45-2.5%$35.00+160.2%+67.5%$42.91M$1M-2.979Positive NewsGap Down Related Companies and Tools Related Companies Kezar Life Sciences Competitors Aileron Therapeutics Competitors Celularity Competitors Nabriva Therapeutics Competitors Virios Therapeutics Competitors Iterum Therapeutics Competitors SCYNEXIS Competitors VYNE Therapeutics Competitors Precision BioSciences Competitors vTv Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APLM) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLM Stock Alerts